Abstract:Engineering peptide-based targeting agents with residues for site-specific and stable complexation of radionuclides is a highly desirable strategy for producing diagnostic and therapeutic agents for cancer and other diseases. In this report, a model N-S-N-py ligand (3) and a cysteine-derived alpha-melanocyte stimulating hormone (alpha-MSH) peptide (6) were used as novel demonstrations of a widely applicable chelation strategy for incorporation of the [M-I(CO)(3)](+) (M = Re, Tc-99m) core into peptide-based molecules for radiopharmaceutical applications. The structural details of the core ligand metal complexes as model systems were demonstrated by full chemical characterization of fac-[Re-I(CO)(3)(N,S,N-py-3)](+) (4) and comparative high-performance liquid chromatography (HPLC) analysis between 4 and [Tc-99m(I)(CO)(3)(N,S,N-py-3)](+) (4a). The alpha-MSH analogue bearing the N-S-N-py chelate on a modified cysteine residue (6) was generated and complexed with [M-I(CO)(3)](+) to confirm the chelation strategy's utility when applied in a peptide-based targeting agent. Characterization of the Re-I(CO)(3)-6 peptide conjugate (7) confirmed the efficient incorporation of the metal center, and the Tc-99m(I)(CO)(3)-6 analogue (7a) was explored as a potential single photon emission computed tomography (SPECT) compound for imaging the melanocortin 1 receptor (MC1R) in melanoma. Peptide 7a showed excellent radiolabeling yields and in vitro stability during amino acid challenge and serum stability assays. In vitro B16F10 melanoma cell uptake of 7a reached a modest value of 2.3 +/- 0.08% of applied activity at 2 h at 37 degrees C, while this uptake was significantly reduced by coincubation with a nonlabeled a-MSH analogue, NAPamide (3.2 mu M) (P < 0.05). In vivo SPECT/X-ray computed tomography (SPECT/CT) imaging and biodistribution of 7a were evaluated in a B16F10 melanoma xenografted mouse model SPECT/CT imaging clearly visualized the tumor at 1 h post injection (p.i.) with high tumor-to-background contrast Blocking studies with coinjected NAPamide (10 mg per kg of mouse body weight) confirmed the in vivo specificity of 7a for MC1R-positive tumors. Biodistribution results with 7a yielded a moderate tumor uptake of 1.20 +/- 0.09 percentage of the injected radioactive dose per gram of tissue (%ID/g) at 1 h p.i. Relatively high uptake of 7a was also seen in the kidneys and liver at 1 h p.i. (6.55 +/- 0.36% ID/g and 444 +/- 0.17% ID/g, respectively), although reduced kidney uptake was seen at 4 h p.i. (3.20 +/- 0.48% ID/g). These results demonstrate the utility of the novel [M-I(CO)(3)](+) chelation strategy when applied in a targeting peptide.

Synthesis of novel N3S pseudo-peptide and biodistribution of 99Tcm-pseudo-peptide complexes in mice

[Synthesis of New N3S Pseudo-Peptide Complexes and Biodistribution in Mice].

SYNTHESIS OF LABELED PEPTIDE COMPLEXES WITH TECHNETIUM-99m AND BIODISTRIBUTION IN MICE

Synthesis of Labelled Small Peptide Complexes for Imaging Agents with Technetium-99M and Biodistribution in Mice.

Synthesis, Biodistribution and Quantitative Structure-Activity Relationship Studies of New 99mtc Labeled Pseudo-Peptide Complexes.

Synthesis and Preliminary Biological Evaluation of a Technetium-99M Labeled Thymidine Analog

Synthesis and Biodistribution of the 99m Tc Nitrido Complex with 2-(4-nitro-1h-imidazolyl)ethyl Dithiocarbamate (NIET)

Preparation and Prelminary Biodistribution in Mice of 99Mtcn-Bmpbda for Myocardial Perfusion Imaging

Biodistribution and SPECT Imaging Study Of99mtc Labeling NGR Peptide in Nude Mice Bearing Human HepG2 Hepatoma

Synthesis and Biodistribution of 99Mtc-Peptides Conjugated Adenine As Tumor Imaging Agents

Novel, cysteine-modified chelation strategy for the incorporation of [MI(CO)3]+ (M = Re, 99mTc) in an α-MSH peptide

Synthesis and Biodistribution of 99Tcm-MAG2-Ade as A Tumor Imaging Agent

Preparation of New Technetium-99m Nns/X Complexes and Selection for Brain Imaging Agent

Preliminary Studies of a Novel Cyclopentadienyl Tricarbonyl Technetium-99M Fatty Acid Derivative for Myocardical Imaging.

Synthesis and biological evaluation of new [Tc(N)(PS)]-based mixed-ligand compounds useful in the design of target-specific radiopharmaceuticals: the 2-methoxyphenylpiperazine dithiocarbamate derivatives as an example

Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m

Experimental Study of 99Tcm-Tri-peptide As a Novel Tumor Imaging Agent

Nitriles Form Mixed-Coligand Complexes with 99Mtc-Hynic-peptide

Synthesis and Biological Evaluation of a Novel 99mtc Cyclopentadienyl Tricarbonyl Complex ([(Cp-R)99mtc(co)3]) for Sigma-2 Receptor Tumor Imaging

Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor

Synthesis, Characterization and Biodistribution of New 99m Tc Nitrido Complexes with Derivatives of Alkyl Xanthates